Nephros (NEPH) director awarded 3,574 shares and holds options expiring 2034–2035

Rhea-AI Filing Summary

Nephros Inc. director Arthur H. Amron reported an equity grant of 3,574 shares of Common Stock, issued in lieu of cash fees for board service. The shares were granted at no cash cost, bringing his direct Common Stock holdings to 138,456 shares after the transaction.

He also reports outstanding stock options to purchase 7,050 shares of Common Stock at an exercise price of $1.47 per share expiring on January 1, 2035, and options on 7,323 shares at $2.14 per share expiring on May 14, 2034. Footnotes indicate these options vest in equal annual installments on specified future dates.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Amron Arthur H

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,574	$0.00	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Common Stock — 138,456 shares (Direct, null); Stock Option (Right to Buy) — 7,323 shares (Direct, null)

Footnotes (1)

1. Shares issued to reporting person in lieu of cash fees for board service. This option vests as to 2,441 shares on each of 5/14/24, 5/14/25 and 5/14/26. This option vests as to 2,350 shares on each of 1/1/25, 1/1/26 and 1/1/27.

Key Figures

Equity grant: 3,574 shares Post-transaction holdings: 138,456 shares Option exercise price: $1.47/share +3 more

6 metrics

Equity grant 3,574 shares Common Stock issued in lieu of cash board fees

Post-transaction holdings 138,456 shares Common Stock directly held after grant

Option exercise price $1.47/share Stock option on 7,050 underlying shares, expiring January 1, 2035

Underlying shares (option 1) 7,050 shares Common Stock underlying $1.47 options, expiring January 1, 2035

Option exercise price $2.14/share Stock option on 7,323 underlying shares, expiring May 14, 2034

Underlying shares (option 2) 7,323 shares Common Stock underlying $2.14 options, expiring May 14, 2034

Key Terms

Stock Option (Right to Buy), grant/award acquisition, in lieu of cash fees for board service, Common Stock, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

in lieu of cash fees for board service financial

"Shares issued to reporting person in lieu of cash fees for board service."

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

exercise price financial

"exercisePrice: 1.4700 and 2.1400 indicate option exercise price per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Amron Arthur H

(Last) (First) (Middle)

C/O NEPHROS, INC., 380 LACKAWANNA PLACE

(Street)

SOUTH ORANGE NEW JERSEY 07079

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEPHROS INC [ NEPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/11/2026		A		3,574(1)	A	$0	138,456	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.14							(2)	05/14/2034	Common Stock	7,323		7,323	D
Stock Option (Right to Buy)	$1.47							(3)	01/01/2035	Common Stock	7,050		7,050	D

Explanation of Responses:

1. Shares issued to reporting person in lieu of cash fees for board service.

2. This option vests as to 2,441 shares on each of 5/14/24, 5/14/25 and 5/14/26.

3. This option vests as to 2,350 shares on each of 1/1/25, 1/1/26 and 1/1/27.

	/s/ Arthur H. Amron	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Nephros (NEPH) director Arthur H. Amron report?

Arthur H. Amron reported receiving 3,574 shares of Nephros Common Stock as an equity grant. These shares were issued in lieu of cash fees for his board service, representing compensation rather than an open-market purchase or sale.

How many Nephros (NEPH) shares does Arthur H. Amron hold after this filing?

Following the grant, Arthur H. Amron directly holds 138,456 shares of Nephros Common Stock. This figure reflects his position after receiving 3,574 shares issued as compensation in lieu of cash fees for serving on the company’s board.

What stock options does Arthur H. Amron hold in Nephros (NEPH)?

He holds stock options linked to 7,050 shares of Common Stock at an exercise price of $1.47 expiring January 1, 2035, and options on 7,323 shares at $2.14 expiring May 14, 2034, providing potential future share acquisitions.

Is the Nephros (NEPH) insider transaction a market buy or sell?

The reported transaction is a grant/award acquisition, not a market buy or sell. Amron received 3,574 shares at a stated price of $0.00 per share as compensation, replacing cash fees for his service on the Nephros board of directors.

How do the Nephros (NEPH) option grants to Arthur H. Amron vest?

One option vests as to 2,441 shares on each of May 14, 2024, 2025, and 2026. Another vests as to 2,350 shares on each of January 1, 2025, 2026, and 2027, spreading his ability to exercise over multiple years.